Stockreport

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

Vaxcyte, Inc.  (PCVX) 
PDF SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to [Read more]